methyl (4'-hydroxy-1,1'-biphenyl-3-yl)acetate | 885681-21-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (4'-hydroxy-1,1'-biphenyl-3-yl)acetate
• 英文别名: methyl (4'-hydroxybiphenyl-3-yl)acetate；methyl 2-[3-(4-hydroxyphenyl)phenyl]acetate
• CAS: 885681-21-0
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: PRGUMUCFQSRING-UHFFFAOYSA-N

物化性质

• 沸点：
  378.5±22.0 °C(Predicted)
• 密度：
  1.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (4'-hydroxy-1,1'-biphenyl-3-yl)acetate 在 三丁基膦 、 对甲苯磺酸 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 生成 methyl (4'-{[2-formyl-3-hydroxy-4-(trifluoromethyl)benzyl]oxy}-1,1'-biphenyl-3-yl)acetate
  参考文献：
  名称：

  Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists

  摘要：

  To obtain potent liver X receptor (LXR) agonists, a structure-activity relationship study was performed on a series of tert-butyl benzoate analogs. As the crystal structure analysis suggested applicable interactions between the LXR ligand-binding domain and the ligands, two key functional groups were introduced. The introduction of the hydroxyl group on the C6-position of the benzoate part enhanced the agonistic activity in a cell-based assay, and the carboxyl group in terminal improved the pharmacokinetic profile in mice, respectively. The obtained compound 32b increased blood ABCA1 mRNA expression without plasma TG elevation in both mice and cynomolgus monkeys. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.07.047
• 作为产物：
  描述：

  3-溴苯乙酸 在 四(三苯基膦)钯 、 硫酸 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 24.0h， 生成 methyl (4'-hydroxy-1,1'-biphenyl-3-yl)acetate
  参考文献：
  名称：

  Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease

  摘要：

  DOI：

  10.1021/acs.jmedchem.2c01918

文献信息

• Carboxylic acid derivative and medicine comprising salt or ester of the same
  申请人：——

  公开号：US20040214888A1

  公开（公告）日：2004-10-28

  The present invention provides novel carboxylic acid derivatives useful as an insulin sensitizer, a salt thereof or a hydrate of them, and a medicament comprising the derivative as the active ingredient. Specifically, it provides a carboxylic acid derivative represented by the following formula: 1 (wherein L represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; M represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; T represents a single bond, or a C1 to C3 alkylene group, a C2 to C3 alkenylene group or a C2 to C3 alkynylene group, each of which may have one or more substituent groups; W represents a carboxyl group; X represents a single bond, an oxygen atom, or a group represented by the various substituent groups including —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or a sulfur atom; R X1 represents a hydrogen atom, a cyano group, a formyl group, or various groups including a C1 to C6 alkyl group and a C1 to C6 hydroxyalkyl group, each of which may have one or more substituent groups), ONR X1 CQ 1 —, —NR X1 CQ 1 —, —CQ 1 NR X1 —, —NR X1a CQ 1 NR X1b —, —Q 2 SO 2 — and —SO 2 Q 2 —; Y represents a 5 to 14-membered aromatic group which may have one or more substituent groups and one or more hetero atoms, or a C3 to C7 alicyclic hydrocarbon group; and the rings Z and U may be the same as or different from each other and each represents a 5 to 14-membered aromatic group which may have 1 to 4 substituent groups and one or more hetero atoms, and the ring may be partially saturated.), a salt thereof, an ester thereof or a hydrate of them.

  本发明提供了一种新型羧酸衍生物，可用作胰岛素增敏剂，其盐或其水合物，以及包含该衍生物作为活性成分的药物。具体而言，本发明提供了一种由以下式子表示的羧酸衍生物：1（其中L表示单键，或C1至C6烷基，C2至C6烯基或C2至C6炔基，每个基团都可以有一个或多个取代基；M表示单键，或C1至C6烷基，C2至C6烯基或C2至C6炔基，每个基团都可以有一个或多个取代基；T表示单键，或C1至C3烷基，C2至C3烯基或C2至C3炔基，每个基团都可以有一个或多个取代基；W表示羧基；X表示单键，氧原子，或由各种取代基表示的基团，包括-NRX1CQ1O-（其中Q1表示氧原子或硫原子；RX1表示氢原子，氰基，甲酰基或各种基团，包括C1至C6烷基和C1至C6羟基烷基，每个基团都可以有一个或多个取代基），ONRX1CQ1-，-NRX1CQ1-，-CQ1NRX1-，-NRX1aCQ1NRX1b-，-Q2SO2-和-SO2Q2-；Y表示一个具有1个或多个取代基和1个或多个杂原子的5至14环芳基，或一个C3至C7脂环烃基；环Z和环U可以相同或不同，每个环表示一个具有1至4个取代基和1个或多个杂原子的5至14环芳基，环可能部分饱和），其盐，酯或其水合物。
• Benzene Compound Having 2 or More Substituents
  申请人：Tamaki Kazuhiko

  公开号：US20080004301A1

  公开（公告）日：2008-01-03

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R 1 : —COR 9 (wherein R 9 : alkyl, optionally substituted alkoxy or optionally substituted amino); R 2 : H, OH, alkoxy, optionally substituted amino, etc.; R 3 : H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R 4 and R 5 : H, optionally substituted alkyl, halogeno, etc.; R 6 and R 7 : H, alkyl; R 8 : —X 2 R 10 [wherein R 10 : —COR 11 (wherein R 11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), —SO 2 R 12 (wherein R 12 : optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X 2 : single bond, optionally substituted alkylene, etc.]; X 1 : —NH—, —O—, —S—, etc.; Y 1 : optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y 2 : optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优越的LXR调节剂。化合物的一般式(I)如下：[其中R1：-COR9（其中R9：烷基，可选地取代的烷氧基或可选地取代的氨基）；R2：H，OH，烷氧基，可选地取代的氨基等；R3：H，可选地取代的烷基，环烷基，可选地取代的烷氧基，可选地取代的氨基，卤素等；R4和R5：H，可选地取代的烷基，卤素等；R6和R7：H，烷基；R8：-X2R10 [其中R10：-COR11（其中R11：OH，可选地取代的烷氧基，可选地取代的氨基等），-SO2R12（其中R12：可选地取代的烷基，可选地取代的氨基等），四唑-5-基等；X2：单键，可选地取代的烷基等]；X1：-NH-，-O-，-S-等；Y1：可选地取代的苯基，可选地取代的5-至6-成员芳香杂环基；Y2：可选地取代的芳基，可选地取代的杂环基等]。
• Benzene compound having 2 or more substituents
  申请人：Daiichi Sankyo Company, Limited

  公开号：US07923573B2

  公开（公告）日：2011-04-12

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R1: —COR9 (wherein R9: alkyl, optionally substituted alkoxy or optionally substituted amino); R2: H, OH, alkoxy, optionally substituted amino, etc.; R3: H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R4 and R5: H, optionally substituted alkyl, halogeno, etc.; R6 and R7: H, alkyl; R8: —X2R10 [wherein R10: —COR11 (wherein R11: OH, optionally substituted alkoxy, optionally substituted amino, etc.), —SO2R12 (wherein R12: optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X2: single bond, optionally substituted alkylene, etc.]; X1: —NH—, —O—, —S—, etc.; Y1: optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y2: optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优越的LXR调节剂。化合物的一般式表示为(I)：[其中R1：—COR9（其中R9：烷基，可选取代的烷氧基或可选取代的氨基）；R2：H，OH，烷氧基，可选取代的氨基等；R3：H，可选取代的烷基，环烷基，可选取代的烷氧基，可选取代的氨基，卤素等；R4和R5：H，可选取代的烷基，卤素等；R6和R7：H，烷基；R8：—X2R10 [其中R10：—COR11（其中R11：OH，可选取代的烷氧基，可选取代的氨基等），—SO2R12（其中R12：可选取代的烷基，可选取代的氨基等），四唑-5-基等；X2：单键，可选取代的烷基等。]；X1：—NH—，—O—，—S—等；Y1：可选取代的苯基，可选取代的5-至6-成员芳香杂环基；Y2：可选取代的芳基，可选取代的杂环基等。]。
• Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US07687664B2

  公开（公告）日：2010-03-30

  The present invention provides novel carboxylic acid derivatives useful as an insulin sensitizer, a salt thereof or a hydrate of them, and a medicament comprising the derivative as the active ingredient. Specifically, it provides a carboxylic acid derivative represented by the following formula (I): (wherein Y, L, X, T, Z, U, M and W are defined in the specification) and a salt thereof, and ester thereof or a hydrate of them.

  本发明提供了一种新型羧酸衍生物，可用作胰岛素敏化剂，其盐或水合物，以及包含该衍生物作为活性成分的药物。具体而言，提供了一种由以下式（I）表示的羧酸衍生物（其中Y、L、X、T、Z、U、M和W在规范中定义），其盐、酯或水合物。
• WO2006/46593
  申请人：——

  公开号：——

  公开（公告）日：——